diabetes type 2

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

alpha-glucosidase inhibitors

not classified
Study 541 -
Study 656, 1994 -
Campbell et al, 1998 -
Bachmann et al, 1998 -
Koyasu, 2010 -
Chiasson et al, 1994placeboExploratory -
Hasche et al, 1999placeboExploratory -
Josse et al, 2003placeboExploratory -
Halimi, 2000errorplacebo (add on to met)Exploratory -
Rosenstock, 1998errorplacebo (add on to met)Exploratory negative
Van Gaal, 2001miglitolplacebo (add on to met)Exploratory negative

angiotensin renin system blockade

not classified
HOPE (diabetic subgroup), 2000ACE inhibitorsplaceboExploratory suggesting
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000ACE inhibitorcalcium-channel blockerExploratory negative
STOP-2 (ACEI, diabetic subgroup), 2000ACE inhibitordiuretic or beta-blockerExploratory negative
captopril
UKPDS 38, 1998captopril or atenololcontrolExploratory suggesting
UKPDS 39, 1998captoprilatenololExploratory negative
CAPP (diabetic subgroup), 1999captoprildiuretic and/or beta-blockersExploratory suggesting
irbesartan
IPDM (150mg), 2001irbesartanplaceboExploratory suggesting
IDNT (irbesartan vs pbo), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002lisinoprilchlorthalidoneExploratory negative
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453negative

angiotensin-receptor blockers

not classified
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
irbesartan
IPDM (150mg), 2001irbesartanplaceboExploratory suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453negative

anti hypertensive agents

not classified
INVEST (subgroup), 2003verapamilcontrolnegative
HOPE (diabetic subgroup), 2000ACE inhibitorsplaceboExploratory suggesting
SCAT (diabetic subgroup), 2000enalaprilplaceboExploratory -
SOLVD (subgroup), 1996enalaprilplacebonegative
ACTION, 1998nifedipineplacebonegative
PROGRESS (diabetic subgroup), 2001perindoprilplaceboExploratory suggesting
EUROPA (PERSUADE substudy), 2005perindoprilplaceboExploratory negative
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias -
ADVANCE, 2007perindopril and indapamideplaceboNCT00145925Low risk of bias suggesting
PROFESS, 2008telmisartanplacebo -
ACCORD (blood pressure), 2010intensiveusualNCT00000620Risk of bias suggesting
HOT <=80 (diabetic subgroup), 1998intensiveusualExploratory suggesting
ABCD normotensives, 1993intensiveusualExploratory suggesting
JMIC-B (diabetic subgroup), 2004nifedipineACE inhibitorExploratory negative
NAGOYA HEART, 2011valsartanamlodipineNCT00129233Risk of bias negative
ASCOT (subgroup), 2008amlodipineatenololExploratory suggesting
ACCOMPLISH (diabetic subgroup), 2010benazepril + amlodipinebenazepril + hydrochlorothiazideNCT00170950Exploratory suggesting
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000ACE inhibitorcalcium-channel blockerExploratory negative
NORDIL (diabetic subgroup), 2000diltiazemdiuretic and/or beta-blockerExploratory negative
STOP-2 (ACEI, diabetic subgroup), 2000ACE inhibitordiuretic or beta-blockerExploratory negative
STOP-2 (CCB, diabetic subgroup), 2000calcium-channel blockerdiuretic or beta-blockerExploratory negative
DETAIL, 2004temisartanenalaprilExploratory negative
GEMINI, 2004carvedilolmetoprololExploratory negative
amlodipine
IDNT (amlodipine vs PBO), 2001amlodipineplaceboLow risk of bias negative
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002amlodipinechlorthalidoneExploratory negative
FACET, 1997amlodipinefosinoprilRisk of bias suggesting
candesartan
SCOPE (diabetic subgroup), 2003candesartancontrolExploratory negative
captopril
UKPDS 38, 1998captopril or atenololcontrolExploratory suggesting
UKPDS 39, 1998captoprilatenololExploratory negative
CAPP (diabetic subgroup), 1999captoprildiuretic and/or beta-blockersExploratory suggesting
chlorthalidone
SHEP (diabetic subgroup), 1996chlorthalidoneplaceboExploratory suggesting
intensive blood pressure lowering strategies
ABCD target (H) , 2000more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting
ABCD target (N) , 2002more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting
irbesartan
IPDM (150mg), 2001irbesartanplaceboExploratory suggesting
IDNT (irbesartan vs pbo), 2001irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipineLow risk of bias suggesting
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002lisinoprilchlorthalidoneExploratory negative
losartan
RENAAL, 2001losartanplaceboLow risk of bias suggesting
LIFE (diabetic subgroup), 2002losartanatenololExploratory suggesting
metoprolol
MERIT-HF, 2005metoprololplacebonegative
nidrendipine
Syst-Eur (diabetic subgroup), 1999nitrendipineplaceboExploratory suggesting
nifedipine
INSIGHT (diabetic subgroup), 2000nifedipinecoamilozideExploratory negative
nisoldipine
ABCD (hypertension), 1998nisoldipineenalaprilExploratory suggesting
olmesartan
ROADMAP, 2010olmesartanplaceboNCT00185159Low risk of bias suggesting
ORIENTolmesartanplaceboNCT00141453negative
ramipril
DIABHYCAR, 2004ramiprilplaceboLow risk of bias negative
DREAM, 2008ramiprilplacebonegative

antidiabetic drugs

not classified
Cefalu, 1998 -
Hermann, 1994 -
Charpentier, 2001 -
YSRE0001repaglinide???NCT00336310 -
UGDPinsulincontrolsuggesting
UKPDS 33insulincontrolnegative
Derosa , 2009nateglinideglibenclamide (add on MET) -
AGEE-3783repaglinidegliclazideNCT01022762 -
PRESERVE-betanateglinideglyburide (add on MET) -
AGEE-1524repaglinide + insulininsulinNCT00799448 -
AGEE-3020repaglinide + insulininsulin -
GLORIAmitiglinide+vogliboseinsulin glargineNCT00663884 -
Horton DOUBLON, 2000nateglinide + metforminmetformin -
ReMetrepaglinideMetforminNCT00118950 -
AGEE-1411repaglinide + metforminmetforminNCT01465152 -
ReformrepaglinideMetformin (add on insulin)NCT00118963 -
CDJN608AUS13 nateglinideplacebo -
CDJN608AUS13 nateglinideplacebo -
CDJN608A ES03nateglinideplacebo -
NAVIGATORnateglinideplacebo -
Schwarz , 2008nateglinideplacebo -
Schwarz (study 2), 2008nateglinideplacebo -
Dashora , 2007nateglinideplacebo (add on insulin) -
Juurinen , 2009nateglinideplacebo (add on insulin+MET) -
NCT01037842mitiglinideplacebo (add on MET)NCT01037842 -
EX-1510-CT-003mitiglinideplacebo (add on MET)NCT00519142 -
NCT00402909nateglinideplacebo (add on standard treatment)NCT00402909 -
026-CL-004 ongoing nateglinideplacebo (add on TZD)NCT00189774 ongoing
AGEE-1411metformin + repagliniderepaglinideNCT01465152 -
Rosenstock , 2004nategliniderepaglinide -
AGEE-3705repaglinide + metforminrepaglinideNCT00819741 -
AGEE-3018repaglinide + metforminrepaglinide -
Raskin , 2009repaglinide + metforminrosiglitazone + metforminNCT00399711 -
AGEE-3017repaglinide + metforminSU or METNCT00568984 -
albiglutide
Rosenstock (30 mg weekly), 2009albiglutide weeklyplacebo (add on MET)NCT00518115Exploratory suggesting
alogliptin
Nauck, 2009alogliptinplacebo (add on MET)NCT00286442Exploratory negative
dapagliflozin
Bailey (MB102014), 2010dapagliflozinplacebo (add on MET)NCT00528879Exploratory -
glimeripide
Study 201 (Goldberg), 1996glimepirideplaceboExploratory -
Schade, 1998glimepirideplacebo -
Rosenstock, 1996glimepirideplacebo -
Luis Bautista, 2003glimepirideplacebo -
Kaneko, 1993glimepirideplacebo -
Study 202glimepirideplacebo -
Riddle, 1994glimepirideplacebo (add on insulin) -
Charpentier, 2001glimepirideplacebo (add on MET)negative
Draeger, 1996glimepirideglibenclamideLow risk of bias -
Protocol 311glimepirideglibenclamide -
Charpentier (301F)glimepiridegliclazide -
Inukai, 2005glimepiridegliclazide or glibenclamide -
Sonnenberg, 1997glimepiride odglimepiride bid -
Clark (301), 1997glimepirideglipizide -
Dills, 1996glimepirideglyburideExploratory -
glipizide
Goldsteinglipizidecontrol (add on MET) -
Rosenstock, 1993glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Birkeland, 1994glipizideglyburide -
Simonson, 1997glipizideplacebo -
Testa, 1998glipizideplacebo -
glyburide
Hermann, 1991glibenclamidec (add on MET) -
DeFronzo, 1995glyburidec (add on MET) -
Erle, 1999glyburidec (add on MET) -
Marre (ass), 2002glibenclamidecontrol (add on MET) -
Tosi, 2003glibenclamidecontrol (add on MET) -
Blonde, 2002glyburidecontrol (add on MET) -
Garber, 2003glyburidecontrol (add on MET) -
Garber, 2002glyburideplacebo -
Vray, 1995glyburideplacebo -
linagliptin
Gallwitz, 2012linagliptinglimepiride (add on MET)NCT00622284 -
linagliptin 1218.62 ongoing linagliptin low doselinagliptinNCT01012037 ongoing
OwenslinagliptinMetformin + sulfonylureaNCT00602472 -
Del PratolinagliptinplaceboNCT00621140 -
linagliptin 1218.65 ongoing linagliptinplacebo (add on MET)NCT01215097 ongoing
linagliptin 1218.61 ongoing linagliptinplacebo (add on MET+TZD)NCT00996658 ongoing
Lewin, 2010linagliptinplacebo (add on SU)NCT00819091 -
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazoneNCT01183013 ongoing
liraglutide
NN2211-1799 ongoing liraglutide other dosesplaceboNCT00620282 ongoing
LEAD-2 (Nauck) (1.8mg vs placebo), 2009liraglutide 1.8mgplacebo (add on MET)NCT00318461suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009liraglutide 1.2mgplacebo (add on SU)NCT00318422Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009liraglutide 1.8mgplacebo (add on SU)NCT00318422suggesting
NN2211-1701 ongoing liraglutide other dosesplacebo (add on SU)NCT00395746 ongoing
LEAD-5 (vs placebo), 2009liraglutide 1.8mgplacebo (add on SU+MET)NCT00331851suggesting
LEAD-4 (1.2mg), 2009liraglutide 1.2mgplacebo (add on TZD+MET)NCT00333151suggesting
LEAD-4 (1.8mg), 2009liraglutide 1.8mgplacebo (add on TZD+MET)NCT00333151suggesting
MK-0431-403 ongoing liraglutide other dosessitagliptin (add on MET)NCT01296412 ongoing
LEAD-6, 2009liraglutide 1.8mgexenatide on top MET/SU/MET+SUNCT00518882Risk of bias suggesting
Seino, 2010liraglutide other dosesglibenclamideNCT00393718Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009liraglutide 1.8mgglimepiride (add on MET)NCT00318461negative
EAGLE ongoing liraglutide other dosesinsulin glargineNCT01117350 ongoing
LEAD-5 (vs Glargine), 2009liraglutide 1.8mginsulin glargine (add on SU+MET)NCT00331851Risk of bias negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009liraglutide other dosesrosiglitazone (add on SU)NCT00318422Low risk of bias suggesting
Pratley 1.2mg, 2010liraglutide 1.2mgsitagliptinNCT00700817Risk of bias suggesting
Pratley 1.8mg, 2010liraglutide 1.8mgsitagliptinNCT00700817Low risk of bias suggesting
lixisenatide
GETGOAL-Llixisenatideplacebo (add on basal insulin)NCT00715624 -
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin)NCT00975286 ongoing
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin)NCT00866658 ongoing
Ratner DRI6012, 2010lixisenatideplacebo (add on MET)NCT00299871Exploratory -
GETGOAL-M ongoing lixisenatideplacebo (add on MET)NCT00712673 ongoing
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU)NCT01169779 ongoing
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET)NCT00713830 ongoing
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET)NCT00763815 ongoing
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET)NCT00976937 ongoing
mitiglinide
GaomitiglinidenateglinideNCT00461617 -
Kumashiro, 2007mitiglinideon top insulin glargine -
Kaku, 2009mitiglinideplacebo (on top pioglitazone) -
nateglinide
Marre, 2002nateglinideplaceboExploratory -
Horton, 2000nateglinideplacebo -
Hanefeld, 1990nateglinideplacebo -
Saloranta, 2002nateglinideplacebo -
Mari, 2005nateglinideplacebo -
Moses, 2001nateglinideplacebo -
Goldberg, 1998repaglinideplacebo -
Jovanovic, 2000repaglinideplacebo -
Bech, 2003repaglinideplacebo -
Li, 2009nategliniderepaglinide -
Li, 2007nategliniderepaglinide -
Ristic, 2006nateglinidegliclazide (add on MET)Exploratory -
nouveau
Buse, 2011exenatide 20µg/dplacebo (add on insulin)NCT00765817Low risk of bias negative
Fineman, 2003exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET)NCT00039013Low risk of bias negative
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)NCT00039013suggesting
Kim, 2007exenatide weeklyplacebo (add on MET)NCT00103935Exploratory negative
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU)NCT00324363Low risk of bias suggesting
Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)NCT00039026negative
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias negative
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET)NCT00035984Low risk of bias suggesting
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)NCT00099320suggesting
Zinman 20µg/j A MODIFIER, 2007exenatide 20µg/dplacebo (add on TZD+/-MET) -
phase 2 exenatide once monthlyexenatide once monthlyweekly exenatide -
Exenatide Trial 10749exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)negative
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099333Risk of bias negative
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET)NCT00099619Exploratory suggesting
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+METNCT00082407Risk of bias negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargineNCT00641056Risk of bias suggesting
Trial 8078exenatide other dosesinsulin glargine (add on MET/SU) -
pioglitazone
PNFP-014pioglitazone + insulinplacebo (add on insulin)Exploratory negative
OPI-502pioglitazone + insulinplacebo (add on insulin)Exploratory negative
repaglinide
Moses, 1999repaglinidecontrol (add on MET)Exploratory -
Landgraf, 1999repaglinideglibenclamide -
Marbury, 1999repaglinideglibenclamide -
Wolffenbuttel, 1999repaglinideglibenclamide -
Madsbad, 2001repaglinideglipizide -
Lund, 2007repaglinidemetformin -
Raskin, 2001repaglinideon top pioglitazone -
Raskin, 2001repaglinideon top rosiglitazone -
Raskin, 2000repaglinideon top troglitazone -
Chuang, 1999repaglinideplacebo -
Goldberg, 1998repaglinideplaceboExploratory -
Jovanovic, 2000repaglinideplacebo -
Landin-Olsson, 1999repaglinideplacebo (on top bedtime NPH-insulin) -
rosiglitazone
SB-712753/009 rosiglitazoneExploratory -
49653/136 rosiglitazoneplaceboExploratory -
BRL 49653/347 rosiglitazoneplacebo (add on insulin)NCT00054782Exploratory -
49653/085 rosiglitazoneplacebo (add on insulin)Exploratory -
49653/095 rosiglitazoneplacebo (add on insulin)Exploratory -
saxagliptin
saxgliptin, renal studysaxagliptinplacebo (add on current treatment) -
CV181-057saxagliptinplacebo (add on insulin)NCT00757588 -
DeFronzo, 2009saxagliptinplacebo (add on MET)NCT00121667negative
CV181-080saxagliptinplacebo (add on MET)NCT00885378 -
Jadzinsky, 2009saxagliptinplacebo (add on MET)NCT00327015 -
CV181-066saxagliptinplacebo (add on MET)NCT00683657 -
Hollandersaxagliptinplacebo (add on TZD)NCT00295633 -
Rosenstock, 2008saxagliptinplacebo (monotherapy)NCT00950599 -
CV181-011saxagliptinplacebo (monotherapy)NCT00121641 -
CV181-038saxagliptinplacebo (monotherapy)NCT00316082 -
CV181-041saxagliptinplacebo (monotherapy)NCT00374907 -
saxagliptin vs sitagliptinsaxagliptinsitagliptin (add on MET) -
sitagliptin
Charbonnel, 2006sitagliptinplacebo (add on MET)NCT0086515negative
Nauck, 2007sitagliptinplacebo (add on MET)NCT00094770negative
Scott** (sit vs pbo on top met), 2007sitagliptinplacebo (add on MET)negative
Rosenstock (sit on top pio vs pbo), 2006sitagliptinplacebo (on top PIO)NCT00086502suggesting
Hermansen, 2007sitagliptinplacebo (on-top glimepiride+/- metformine)negative
taspoglutide
BC21713 (vs placebo) ongoing taspoglutideplaceboNCT00754988 ongoing
BC20963 ongoing taspoglutideplaceboNCT00744367 ongoing
Nauck 10 once weekly vs PBO, 2009taspoglutide 10mg once weeklyplaceboNCT00423501Exploratory suggesting
Ratner (20mg once weekly), 2010taspoglutideplacebo (add on MET)NCT00460941Exploratory suggesting
BC22092 ongoing taspoglutideplacebo (add on MET)NCT00823992 ongoing
BC21625 ongoing taspoglutideexenatideNCT00717457 ongoing
ZC22565 ongoing taspoglutideinsulin glargineNCT01051011 ongoing
BC20965 ongoing taspoglutideinsulin glargine (add on MET)NCT00755287 ongoing
BC21893 ongoing taspoglutidepioglitazoneNCT00909597 ongoing
vildagliptin
Fonseca, 2007vildagliptinplacebo (add on insulin)NCT00099931suggesting
Ahren, 2004vildagliptinplacebo (add on MET)negative
Bosi, 2007vildagliptinplacebo (add on MET)NCT00099892negative
Goodman, 2009vildagliptinplacebo (add on MET)Exploratory negative
Garber, 2007vildagliptinplacebo (on top pioglitazone)NCT00099853negative
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET)NCT00106340Exploratory suggesting
Bolli, 2008vildagliptinpioglitazone (add on MET)NCT00237237negative
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NCT00101803negative

antioxydants

not classified
POPADAD (antioxydant), 2008combinationplaceboISRCTN53295293Low risk of bias negative

antiplatelets drug

aspirin
JPAD, 2008aspirinno treatmentNCT00110448Risk of bias suggesting
PPP (diabetics sub group), 2003aspirinno treatmentExploratory negative
POPADAD aspirin, 2008aspirinplaceboISRCTN53295293Low risk of bias negative
DAMAD, 1989aspirinplaceboLow risk of bias negative
ETDRS, 1992aspirinplaceboLow risk of bias suggesting
PHS (diabetics sub group), 1989aspirinplaceboLow risk of bias suggesting
WHS (diabetics sub group), 2005aspirinplaceboExploratory suggesting
ASCEND (aspirin) ongoing aspirinplaceboNCT00135226 ongoing
ACCEPT-D ongoing aspirinplaceboISRCTN48110081Risk of bias ongoing
picotamide
Cocozza, 1995picotamideplaceboExploratory negative
sulfinpyrazone
Dutch, 1980sulfinyrazoneplacebonegative
ticlopidine
Birmingham-A, 1979ticlopidineplacebonegative
London diabetes, 1983ticlopidineplacebonegative
TIMAD, 1984ticlopidineplacebonegative
BTRS, 1992ticlopidineplacebonegative
Nyberg, 1984ticlopidineplaceboLow risk of bias negative

cholesterol lowering intervention

not classified
Post CABG (diabetic sub group), 1999aggressive cholesterol-loweringmoderate cholesterol-loweringdiabetic patients type 2 diabetes Exploratory -
atorvastatin
ASCOT (diabetics sub group), 2003atorvastatinplacebodiabetic patients type 2 diabetes Exploratory negative
CARDS, 2004atorvastatinplacebodiabetic type 2 diabetes NCT00327418Low risk of bias conclusive
ASPEN, 2006atorvastatinplacebodiabetic patients trastuzumab-naif type 2 diabetes Low risk of bias negative
TNT (diabetic sub group), 2006atorvastatin high doseatorvastatindiabetic patients type 2 diabetes Exploratory suggesting
ezetimibe
SANDS, 2008aggressive treatmentstandard teatmentdiabetic type 2 diabetes NCT00047424Exploratory negative
fenofibrate
FIELD, 2005fenofibrateplacebodiabetic patients type 2 diabetes ISRCTN64783481Low risk of bias suggesting
ACCORD lipid, 2010fenofibrateplacebo (on top simvastatine)diabetic patients type 2 diabetes NCT00000620Low risk of bias negative
ACCORD lipid (subgroup Eye study), 2010fenofibrateplacebo (on top simvastatine)diabetic patients type 2 diabetes NCT00000620Exploratory suggesting
fluvastatin
LIPS (diabetic sub group), 2002fluvastatinplacebodiabetic patients type 2 diabetes Exploratory suggesting
ALERT (diabetic sub group), 2003fluvastatinplacebodiabetic patients type 2 diabetes Exploratory -
gemfibrozil
HHS (diabetic sub group), 1987gemfibrozilplacebodiabetic patients type 2 diabetes Exploratory -
VA-HIT (diabetic sub group), 1999gemfibrozilplacebodiabetic patients type 2 diabetes Exploratory negative
lovastatin
AFCAPS/TexCAPS (diabetic sub group), 1998lovastatinplacebodiabetic patients type 2 diabetes Exploratory -
pravastatin
PROSPER diabetic (sub group), 2002pravastatinplacebodiabetic patients type 2 diabetes Exploratory negative
LIPID (diabetic sub group), 1998pravastatinplacebodiabetic patients type 2 diabetes Exploratory negative
CARE (diabetic sub group), 1998pravastatinplacebodiabetic patients type 2 diabetes Exploratory suggesting
WOSCOPS (diabetic sub group), 1996pravastatinplacebodiabetic patients type 2 diabetes Exploratory -
GISSI P (diabetic sub group), 2000pravastatinusual carediabetic patients type 2 diabetes Exploratory -
ALLHAT-LLT (diabetic sub group), 2002pravastatinusual carediabetic patients type 2 diabetes Exploratory negative
PROVE IT TIMI 22 (diabetic sub group), 2006pravastatin high dosepravastatindiabetic patients type 2 diabetes Exploratory -
simvastatin
HPS (diabetic sub group), 2002simvastatinplacebodiabetic patients type 2 diabetes Exploratory suggesting
4S (diabetic sub group), 1999simvastatinplacebodiabetic patients type 2 diabetes Exploratory suggesting

glucose lowering for cardiovascular prevention

not classified
ORIGINE, 2012insulin glarginecontrolNCT00069784negative
RECORD, 2013rosiglitazonemetformin/sulfonylureaNCT00379769negative
ACE ongoing acarboseplaceboNCT00829660 ongoing
ALEPREVENTaleglitazarplaceboEUDRACT201200067116 -
ALECARDIO, 2014aleglitazarplaceboNCT01042769Exploratory negative